BMY: Growth Portfolio and Eliquis lift Q3 sales despite one-time charges
Bristol-Myers Squibb's Q3 revenue rose 7% year on year; GAAP diluted EPS was $1.05 and adjusted EPS $1.35, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Bristol-Myers Squibb's third-quarter revenue grew 7% year on year. Gains from its Growth Portfolio and Eliquis more than offset the erosion caused by generic competition to older drugs.
GAAP diluted earnings per share came in at $1.05, while adjusted non-GAAP EPS was $1.35. The company also pointed to pipeline progress and 2026 approvals that advance its growth priorities. The information is reported by TradingView, which notes that its text is an AI-generated summary.
why it matters
The gap between GAAP and adjusted earnings reflects one-time charges that weighed on the bottom line. For investors in the pharma sector, the performance of key drugs and resilience of revenue against generic competition are the main things to watch.
market impact
BMY shares: revenue and key drug growth versus one-time charges give a mixed signal
- BMY shares mixed — revenue and Eliquis growth against one-time charges and generic erosion
tags
instruments
sources
- BMY: Growth and Eliquis lifted Q3 sales, while legacy generics and one-time charges weighed on earnings — TradingView, 29 October 2026 at 15:17 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗